NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Viking Therapeutics, Inc. VKTX
12 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-359.6M
Growth
—
Revenue, FY2025 · full 12-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -359.6
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -47.3%
Each USD of equity lost 47 cents this year.
The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.4 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | −0.4 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −3.19 | −1.01 | −0.91 | −0.90 | −0.71 | −0.54 | −0.36 | −0.38 | −0.79 | −0.90 | −3.68 | −5.23 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −47.3 | −17.9 | −34.8 | −39.7 | −24.6 | −15.1 | −9.0 | −14.2 | −191.4 | −175.7 | · | · |
| Shares out B | 0.11 | 0.11 | 0.10 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.04 | 0.02 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 28 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014